Biology Reference
In-Depth Information
136. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymi-
dylate synthase mRNA levels predict survival for colorectal
cancer patients receiving combination oxaliplatin and fluoro-
uracil chemotherapy. J Clin Oncol 2001;
152. Shao YY, Kuo KT, Hu FC, et al. Predictive and prognostic values
of tau and ERCC1 in advanced breast cancer patients treated with
paclitaxel and cisplatin. Jpn J Clin Oncol 2010;
:286
e
93.
153. Chan SH, Cheung FM, Ng WT, et al. Can the analysis of ERCC1
expression contribute to individualized therapy in nasopharyn-
geal carcinoma? Int J Radiat Oncol Biol Phys 2011;
40
:4298
e
304.
137. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular
markers
19
(5):1414
e
20.
154. Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1
expression predict outcome of patients with locally advanced
bladder cancer
79
in outcome of esophageal cancer. Dis Esophagus
:425
e
32.
138. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian
carcinoma cell lines (A2780/CP70 and MCAS) that are equally
resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Int J Oncol 2000;
2006;
19
receiving adjuvant chemotherapy. Neoplasia
:628
e
36.
155. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL,
Sanford KK, et al. XPD polymorphisms: effects on DNA repair
proficiency. Carcinogenesis 2000;
2010;
12
:555
e
60.
139. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 poly-
morphism is a predictive factor for the tumor response to oxali-
platin/5-fluorouracil combination chemotherapy in patients with
advanced colorectal cancer. Clin Cancer Res 2005;
16
:551
e
5.
156. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision
repair capacity by XPD polymorphisms in lung cancer patients.
Cancer Res 2001;
21
:6212
e
7.
140. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene poly-
morphism as a predictor for clinical outcome in advanced colo-
rectal cancer patients treated with platinum-based chemotherapy.
Clin Adv Hematol Oncol 2003;
11
:1354
e
7.
157. Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo BA. Poly-
morphisms in the DNA repair gene XPD: correlations with risk
and age at onset of basal cell carcinoma. Cancer Epidemiol
Biomarkers Prev 1999;
61
:162
e
6.
141. Metzger R, Danenberg K, Leichman CG, et al. High basal level
gene expression of thymidine phosphorylase (platelet-derived
endothelial cell growth factor) in colorectal tumors is associated
with
1
:77
e
81.
158. Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ultra-
violet damage in the host-cell reactivation assay by polymorphic
XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002;
8
:295
e
9.
159. Seker H, Butkiewicz D, Bowman ED, et al. Functional significance
of XPD polymorphic variants: attenuated apoptosis in human
lymphoblastoid cells with the XPD 312 Asp/Asp genotype.
Cancer Res 2001;
23
nonresponse
to
5-fluorouracil.
Clin
Cancer
Res
:2371
e
6.
142. Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression
of ERCC1, thymidylate synthase, and glutathione S-transferase
P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced
gastric cancer. Ann Oncol 2007;
1998;
4
:7430
e
4.
160. Rzeszowska-Wolny J, Polanska J, Pietrowska M, et al. Influence of
polymorphisms in DNA repair genes XPD, XRCC1 and MGMT
on DNA damage induced by gamma radiation and its repair in
lymphocytes in vitro. Radiat Res 2005;
61
:504
e
9.
143. Yun J, Kim KM, Kim ST, et al. Predictive value of the ERCC1
expression for treatment response and survival in advanced
gastric cancer patients receiving cisplatin-based first-line
chemotherapy. Cancer Res Treat 2010;
18
:132
e
40.
161. Le Morvan V, Bellott R, Moisan F, Mathoulin-Pelissier S, Bonnet J,
Robert J. Relationships between genetic polymorphisms and
anticancer drug cytotoxicity vis-a-vis the NCI-60 panel. Pharma-
cogenomics 2006;
164
:101
e
16.
144. Warnecke-Eberz U, Metzger R, Miyazono F, et al. High specificity
of quantitative excision repair cross-complementing 1 messenger
RNA expression for prediction of minor histopathological
response to neoadjuvant
42
:843
e
52.
162. Zarate RN, Arias F, Bandres E, Cubedo E, Malumbres R, Garcia-
Foncillas J. Xeroderma pigmentosum group D 751 polymorphism
as a predictive factor in resected gastric cancer treated with
chemo-radiotherapy. World J Gastroenterol 2006;
7
radiochemotherapy in esophageal
:3794
e
9.
145. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression
of TS1, GSTP1, and ERCC1 are risk factors for survival in patients
treated with trimodality therapy for esophageal cancer. Clin
Cancer Res 2005;
cancer. Clin Cancer Res 2004;
10
:6032
e
6.
163. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S,
Lenz HJ. A xeroderma pigmentosum group D gene poly-
morphism predicts clinical outcome to platinum-based chemo-
therapy in patients with advanced colorectal cancer. Cancer Res
2001;
12
:2215
e
21.
146. Sobajima J, Haga N, Kumamoto K, Ishibashi K, Ishida H. [ERCC1
and TS expression in chemoradiotherapy treated esophageal squamous
cell carcinoma.] Gan To Kagaku Ryoho 2010;
11
:8654
e
8.
164. Yuan P, Miao XP, Zhang XM, et al. [Polymorphisms in nucleotide
excision repair genes XPC and XPD and clinical responses to platinum-
based chemotherapy in advanced non-small cell lung cancer.] Zhong-
hua Yi Xue Za Zhi 2005;
61
:2394
e
6.
147. Fareed KR, Al-Attar A, Soomro IN, et al. Tumour regression and
ERCC1 nuclear protein expression predict clinical outcome in
patients with gastro-oesophageal cancer
37
:972
e
5.
165. Camps C, Sarries C, Roig B, et al. Assessment of nucleotide
excision repair XPD polymorphisms in the peripheral blood of
gemcitabine/cisplatin-treated advanced non-small-cell
85
treated with neo-
:1600
e
7.
148. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C,
Reed E. ERCC1 and ERCC2 expression in malignant tissues from
ovarian cancer patients. J Natl Cancer Inst 1992;
adjuvant chemotherapy. Br J Cancer 2010;
102
lung
:237
e
41.
166. Chen H, Shao C, Shi H, Mu Y, Sai K, Chen Z. Single nucleotide
polymorphisms and expression of ERCC1 and ERCC2 vis-a-vis
chemotherapy drug cytotoxicity in human glioma. J Neurooncol
2007;
cancer patients. Clin Lung Cancer 2003;
4
:1512
e
7.
149. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E.
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer
tissue correlate with response to platinum-based chemotherapy.
J Clin Invest 1994;
84
:257
e
62.
167. Sakano S, Wada T, Matsumoto H, et al. Single nucleotide poly-
morphisms in DNA repair genes might be prognostic factors in
muscle-invasive bladder cancer patients treated with chemo-
radiotherapy. Br J Cancer 2006;
82
:703
e
8.
150. Doll CM, Prystajecky M, Eliasziw M, et al. Low ERCC1 mRNA
and protein expression are associated with worse survival in
cervical cancer patients treated with radiation alone. Radiother
Oncol 2010;
94
:561
e
70.
168. Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD
predicts treatment outcome and risk of acute myeloid leukemia
following chemotherapy. Blood 2004;
95
:352
e
9.
151. Park JS, Jeon EK, Chun SH, et al. ERCC1 (excision repair cross-
complementation group 1) expression as a predictor for response
of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix
cancer. Gynecol Oncol 2011;
97
:3872
e
7.
169. Vangsted A, Gimsing P, Klausen TW, et al. Polymorphisms in the
genes ERCC2, XRCC3 and CD3EAP influence treatment outcome
104
120
(2):275
e
9.
